低中所得国における医薬品アクセスの現状と2024年ATMインデックスの意義

The 2024 Access to Medicine Index shows modest progress in global pharmaceutical access, but significant improvement potential remains. While Novartis leads, the industry overall has declined since 2022. Challenges such as limited clinical trials in low- and middle-income countries and slow adoption of inclusive business models continue. The article also highlights the need for transparent partnerships and greater corporate responsibility.

The article also examines the performance of Japanese companies, with Takeda ranked 9th, Eisai 14th, Astellas Pharma 15th, and Daiichi Sankyo 18^th.